CN1522246A - 作为微粒体甘油三酯转移蛋白(mtp)和/或载脂蛋白b(apo b)分泌抑制剂的三酰胺取代的吲哚、苯并呋喃及苯并噻吩 - Google Patents
作为微粒体甘油三酯转移蛋白(mtp)和/或载脂蛋白b(apo b)分泌抑制剂的三酰胺取代的吲哚、苯并呋喃及苯并噻吩 Download PDFInfo
- Publication number
- CN1522246A CN1522246A CNA028130219A CN02813021A CN1522246A CN 1522246 A CN1522246 A CN 1522246A CN A028130219 A CNA028130219 A CN A028130219A CN 02813021 A CN02813021 A CN 02813021A CN 1522246 A CN1522246 A CN 1522246A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- methyl
- trifluoromethyl
- compound
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Description
表12 | |||
2-θ角(/°) | 强度(/%) | 2-θ角(/°) | 强度(/%) |
5.673 | 100.00 | 25.654 | 9.48 |
11.359 | 8.38 | 25.699 | 2.71 |
12.848 | 23.61 | 25.767 | 5.84 |
13.354 | 8.19 | 25.862 | 2.18 |
13.930 | 8.67 | 26.425 | 2.02 |
14.091 | 3.57 | 26.665 | 3.22 |
15.374 | 3.21 | 26.894 | 2.36 |
15.750 | 3.88 | 27.054 | 4.25 |
16.668 | 16.53 | 27.556 | 7.66 |
17.501 | 5.36 | 27.983 | 2.97 |
17.691 | 6.87 | 28.071 | 7.04 |
17.790 | 5.31 | 28.547 | 5.53 |
18.073 | 2.47 | 28.763 | 3.60 |
18.886 | 2.17 | 28.771 | 3.31 |
19.361 | 42.54 | 29.351 | 10.87 |
19.363 | 26.18 | 29.578 | 5.76 |
19.575 | 3.55 | 29.983 | 8.44 |
19.633 | 2.40 | 30.830 | 8.48 |
19.922 | 3.34 | 31.115 | 9.03 |
20.103 | 15.17 | 31.746 | 4.06 |
20.216 | 2.38 | 31.807 | 3.79 |
21.352 | 5.08 | 32.401 | 2.28 |
21.417 | 6.47 | 32.540 | 3.47 |
22.022 | 5.00 | 33.326 | 2.08 |
22.750 | 14.75 | 33.802 | 2.28 |
22.817 | 6.19 | 36.240 | 3.98 |
22.832 | 2.63 | 37.491 | 2.71 |
23.948 | 6.50 | 38.312 | 2.03 |
23.954 | 5.24 | 38.360 | 4.67 |
24.322 | 2.66 | 39.406 | 2.45 |
24.399 | 3.20 | 39.752 | 3.11 |
24.471 | 5.84 | 40.510 | 2.81 |
24.681 | 2.98 | 43.483 | 2.17 |
24.761 | 21.22 |
7 | H | 乙基 | 乙基 | 612.658 | 613.2 | 15.158 |
8 | 乙基 | H | 异丙基甲基 | 640.712 | 641.2 | 17.318 |
9 | 乙基 | 甲基 | 苄基 | 688.756 | 689.2 | 19.712 |
10 | 乙基 | 甲基 | 丙基 | 640.712 | 641.2 | 18.505 |
11 | 乙基 | 吡咯烷-1-基 | 638.696 | 639.2 | 16.558 | |
12 | H | H | 丙基 | 598.63 | 599.2 | 13.357 |
13 | H | H | 环丙基甲基 | 610.642 | 611.2 | 13.741 |
14 | 苄基 | H | 异丙基甲基 | 702.783 | 703.2 | 19.25 |
15 | 丙基 | H | 苄基 | 688.756 | 689.2 | 24.897 |
16 | H | 吡咯烷-1-基 | 610.642 | 611.2 | 13.337 | |
17 | H | 甲基 | 吡啶-3-基甲基 | 661.69 | 662.2 | 5.671 |
18 | 甲基 | 甲基 | 吡啶-3-基甲基 | 675.717 | 676.2 | 7.099 |
19 | 苄基 | 甲基 | 吡啶-3-基甲基 | 751.816 | 752.2 | 16.229 |
20 | 乙基 | H | 3-甲基-苄基 | 688.756 | 689.2 | 18.511 |
21 | 苄基 | H | 3-甲基-苄基 | 750.828 | 751.2 | 20.242 |
22 | 苄基 | H | 2-苯基-丙-2-基 | 764.855 | 765.2 | 21.217 |
23 | 苄基 | H | 4-甲基-苄基 | 750.828 | 751.2 | 20.209 |
24 | 甲基 | H | 4-氟-苄基 | 678.693 | 679.2 | 16.585 |
39 | 甲基 | H | 苄基 | 661.69 | 662.8 | 12.95 |
40 | 甲基 | 吗啉-4-基 | 641.65 | 642.5 | 9.72 | |
41 | 甲基 | 吡咯烷-1-基 | 625.65 | 626.5 | 11.44 | |
42 | 甲基 | 甲基 | 吡啶-3-基 | 676.70 | 677.5 | 3.72 |
43 | 甲基 | H | 4-羧酸甲酯 | 719.73 | 720.8 | 12.10 |
49 | 甲基 | H | 甲基 | 吡啶-3-基 | H | 三氟甲基 | 710.16 | 710.2 | 8.513 |
50 | 甲基 | H | H | 丙基 | H | 三氟甲基 | 647.10 | 647.2 | 16.67 |
51 | 甲基 | H | 乙基 | 苄基 | H | 三氟甲基 | 723.20 | 723.2 | 21.392 |
52 | 甲基 | H | 甲基 | 3-氯-苄基 | H | 三氟甲基 | 743.61 | 744.2 | 20.578 |
53 | 甲基 | H | 甲基 | 苄基 | 甲基 | 三氟甲基 | 723.20 | 723.2 | 21.202 |
54 | 甲基 | H | H | 乙基 | 甲基 | 三氟甲基 | 647.10 | 647.2 | 15.615 |
55 | 甲基 | H | H | 异丙基 | 甲基 | 三氟甲基 | 661.1 | 661.2 | 17.161 |
56 | 甲基 | H | 甲基 | 吡啶-3-基 | 甲基 | 三氟甲基 | 724.18 | 724.2 | 9.154 |
57 | H | H | 甲基 | 苄基 | H | 三氟甲基 | 695.14 | 695.2 | 19.131 |
58 | 乙基 | H | 甲基 | 苄基 | H | 三氟甲基 | 723.20 | 723.2 | 21.172 |
59 | 乙基 | H | H | 4-甲氧基-苄基 | H | 三氟甲基 | 739.20 | 739.2 | 18.345 |
60 | 甲基 | 甲基 | 甲基 | 苄基 | H | 三氟甲基 | 709.22 | 709.2 | 8.966 |
61 | 甲氧基甲基 | H | 甲基 | 苄基 | H | 三氟甲基 | 739.20 | 739.2 | 19.677 |
62 | 甲基 | H | H | 丙基 | H | H | 579.10 | 579.2 | 14.388 |
63 | 甲基 | H | H | 异丙基 | H | H | 579.10 | 579.2 | 14.327 |
64 | 甲基 | H | 甲基 | 吡啶-2-基 | H | H | 642.16 | 642.2 | 11.303 |
65 | 甲基 | H | 甲基 | 吡啶-3-基 | H | H | 642.16 | 642.2 | 6.322 |
65b | 甲基 | H | 甲基 | 乙基 | H | 三氟甲基 | 633.12 | 633.2 | 4.318 |
65c | 甲基 | H | H | 4-甲基-苄基 | H | 三氟甲基 | 695.19 | 695.2 | 11.147 |
65d | 甲基 | H | H | 丙基 | H | 三氟甲基 | 633.12 | 633.2 | 6.923 |
65e | 甲基 | H | 乙基 | 乙基 | H | 三氟甲基 | 647.15 | 647.2 | 5.071 |
65f | 甲基 | H | H | 甲基 | H | 三氟甲基 | 605.06 | 605.2 | 5.433 |
实施例 | R1 | 分子量(计算值) | MS(实测值) | HPLC(min) |
113 | 异丙基甲基 | 524.668 | 525.2 | 14.958 |
114 | 2-甲氧基-苯基 | 560.658 | 561.2 | 15.07 |
115 | 2-甲基-5-氯-苯基 | 579.104 | 579.2 | 16.683 |
116 | 1-羟基-环丙-1-基 | 552.679 | 553.2 | 13.013 |
117 | 2-甲基-4-氯-苯基 | 579.104 | 579.2 | 16.651 |
118 | (降冰片-2-基)-甲基 | 562.718 | 563.2 | 17.288 |
119 | 环丁基 | 508.625 | 509.2 | 11.734 |
120 | 苯氧基-乙基-甲基 | 588.712 | 589.2 | 17.118 |
121 | 5-溴-呋喃-2-基 | 599.489 | 600.2 | 14.651 |
122 | 1-苯基-环戊-1-基 | 598.751 | 599.2 | 18.913 |
123 | 萘-1-基 | 580.692 | 581.2 | 15.995 |
124 | 3-氯-噻吩-2-基 | 571.102 | 571.2 | 15.847 |
125 | 全氟乙基 | 572.539 | 573.2 | 16.771 |
126 | 2-(吡咯-1-基)-苯基 | 595.707 | 596.2 | 15.497 |
127 | 异喹啉-1-基 | 581.68 | 582.2 | 16.432 |
填料/稀释剂 | 崩解剂/润湿剂 | 甜味剂 | 润滑剂 |
微晶纤维素/甘露醇1∶2(93.5%) | Ac-Di-Sol 3% | - | 硬脂酸镁1% |
甘露醇/Dcp 2∶1(93.5%) | Ac-Di-Sol 3% | - | 硬脂酸镁1% |
甘露醇/Dcp 2∶1(93.5%) | Ac-Di-Sol 3% | - | 硬脂酸镁1% |
甘露醇/Fast Flo乳糖1∶2(93.5%) | Ac-Di-Sol 3% | - | 硬脂酸镁1% |
微晶纤维素/甘露醇1∶2(73.5%) | Ac-Di-Sol 3% | (啤)酒酵母20% | 硬脂酸镁1% |
甘露醇/Dcp 2∶1(73.5%) | Ac-Di-Sol 3% | (啤)酒酵母20% | 硬脂酸镁1% |
微晶纤维素/甘露醇1∶2(92.5%) | Ac-Di-Sol 3%+Sls 1% | - | 硬脂酸镁1% |
微晶纤维素/甘露醇1∶2(72.5%) | Ac-Di-Sol 3%+Sls 1% | (啤)酒酵母20% | 硬脂酸镁1% |
微晶纤维素/甘露醇1∶2(92.5%) | Explotab4% | - | 硬脂酸镁1% |
微晶纤维素/甘露醇1∶2(93.5%) | Ac-Di-Sol 3% | - | 十八烷基富马酸钠1% |
甘露醇/Dcp 2∶1(62.5%) | Ac-Di-Sol 3%Sls=1% | 酵母提取物10%(啤)酒酵母20% | 硬脂酸镁1% |
商标 | 化学组成 | 商业来源 |
Triacetin | 三乙酸甘油酯 | Abitec |
Capmul CMC | 辛酸/癸酸甘油酯 | Abitec |
Miglyol 812 | 癸酸/琥珀酸甘油三酯 | Condea |
Miglyol 829 | aprylate/癸酸/琥珀酸甘油三酯 | Condea |
Miglyol 840 | 二辛酸/二癸酸丙二醇酯 | Condea |
Labrafil M 1944CS | 油酰聚二乙醇-6-甘油酯 | Gattefosse |
Maisine 35-1 | Glyceryl monolinoate | Gattefosse |
Peceol | 甘油单油酸酯 | Gattefosse |
Captex 355 EP | 中链甘油三酯 | Abitec |
Crodamol GTC/C | 中链甘油三酯 | Croda |
Labrafac CC | 中链甘油三酯 | Gattefosse |
Claims (15)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30164401P | 2001-06-28 | 2001-06-28 | |
US60/301,644 | 2001-06-28 | ||
PCT/IB2002/001876 WO2003002533A1 (en) | 2001-06-28 | 2002-05-24 | Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (mtp) and/or apolipoprotein b (apo b) secretion |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006100941142A Division CN1880304B (zh) | 2001-06-28 | 2002-05-24 | 三酰胺取代的吲哚、苯并呋喃及苯并噻吩 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1522246A true CN1522246A (zh) | 2004-08-18 |
CN1522246B CN1522246B (zh) | 2010-04-21 |
Family
ID=23164253
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN028130219A Expired - Fee Related CN1522246B (zh) | 2001-06-28 | 2002-05-24 | 三酰胺取代的吲哚、苯并呋喃及苯并噻吩 |
CN2006100941142A Expired - Fee Related CN1880304B (zh) | 2001-06-28 | 2002-05-24 | 三酰胺取代的吲哚、苯并呋喃及苯并噻吩 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006100941142A Expired - Fee Related CN1880304B (zh) | 2001-06-28 | 2002-05-24 | 三酰胺取代的吲哚、苯并呋喃及苯并噻吩 |
Country Status (47)
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022111222A1 (zh) * | 2020-11-26 | 2022-06-02 | 安润医药科技(苏州)有限公司 | 作为前列腺素ep4受体拮抗剂的酰胺衍生物及其用途 |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1330444B1 (en) | 2000-11-01 | 2011-03-23 | Millennium Pharmaceuticals, Inc. | Nitrogenous heterocyclic compounds and process for making them |
JP4139325B2 (ja) * | 2001-06-28 | 2008-08-27 | ファイザー・プロダクツ・インク | ミクロソーム・トリグリセリド・トランスファータンパク質(mtp)及び/又はアポリポタンパク質b(apob)分泌の阻害剤としてのトリアミド置換インドール、ベンゾフラン及びベンゾチオフェン |
AU2003207438A1 (en) * | 2002-01-02 | 2003-07-24 | Visen Medical, Inc. | Amine functionalized superparamagnetic nanoparticles for the synthesis of bioconjugates and uses therefor |
WO2004071458A2 (en) * | 2003-02-13 | 2004-08-26 | Albert Einstein College Of Medicine Of Yeshiva University | REGULATION OF FOOD INTAKE AND GLUCOSE PRODUCTION BY MODULATION OF LONG-CHAIN FATTY ACYL-CoA LEVELS IN THE HYPOTHALAMUS |
JP2006528700A (ja) * | 2003-05-20 | 2006-12-21 | エリモス・ファーマスーティカルズ・エルエルシー | 肥満の治療のためのカテコールブタンの投与のための方法と組成物 |
US7598046B2 (en) | 2003-06-19 | 2009-10-06 | Laboratories Serono Sa | Use of prion conversion modulating agents |
CA2545443A1 (en) * | 2003-11-14 | 2005-05-26 | Pfizer Products Inc. | Solid amorphous dispersions of an mtp inhibitor for treatment of obesity |
EP1716137A1 (en) | 2004-02-04 | 2006-11-02 | Pfizer Products Incorporated | Substituted quinoline compounds |
CA2910191C (en) | 2004-03-05 | 2022-03-08 | The Trustees Of The Univeristy Of Pennsylvania | The use of mtp inhibitors for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
FR2873694B1 (fr) | 2004-07-27 | 2006-12-08 | Merck Sante Soc Par Actions Si | Nouveaux aza-indoles inhibiteurs de la mtp et apob |
WO2006041922A2 (en) * | 2004-10-08 | 2006-04-20 | Dara Biosciences, Inc. | Agents and methods for administration to the central nervous system |
PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
US20070026079A1 (en) * | 2005-02-14 | 2007-02-01 | Louis Herlands | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels |
EP1890767A2 (en) * | 2005-05-27 | 2008-02-27 | Pfizer Products Inc. | Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss |
US7417066B2 (en) | 2005-06-08 | 2008-08-26 | Schering Ag | Inhibitors of soluble adenylate cyclase |
DE102005027274A1 (de) * | 2005-06-08 | 2006-12-14 | Schering Ag | Inhibitoren der löslichen Adenylatzyklase |
EP1912968A1 (en) * | 2005-08-04 | 2008-04-23 | Pfizer Limited | Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds |
US20080253985A1 (en) * | 2005-10-18 | 2008-10-16 | Wisler Gerald L | Compositions for Lowering Serum Cholesterol and/or Triglycerides |
US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
EP1954137A4 (en) * | 2005-11-18 | 2008-12-17 | Janssen Pharmaceutica Nv | 2-KETO-OXAZOLE AS MODULATORS OF FATTY ACID AMIDHYDROLASE |
US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
EP1973575B1 (en) | 2005-12-22 | 2019-07-24 | Visen Medical, Inc. | Biocompatible fluorescent metal oxide nanoparticles |
US8383660B2 (en) | 2006-03-10 | 2013-02-26 | Pfizer Inc. | Dibenzyl amine compounds and derivatives |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
DK3091011T3 (en) | 2006-04-07 | 2018-02-26 | Vertex Pharma | MODULATORS OF ATP BINDING CASSETTE TRANSPORT |
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
KR20090064478A (ko) | 2006-11-13 | 2009-06-18 | 화이자 프로덕츠 인크. | 디아릴, 디피리디닐 및 아릴-피리디닐 유도체, 및 이들의 용도 |
EP2094643B1 (en) | 2006-12-01 | 2012-02-29 | Bristol-Myers Squibb Company | N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
US20080161279A1 (en) * | 2006-12-21 | 2008-07-03 | Wisler Gerald L | Methods of Treating Obesity |
WO2008100423A1 (en) * | 2007-02-09 | 2008-08-21 | Sirtris Pharmaceuticals, Inc. | Gut microsomal triglyceride transport protein inhibitors |
EP2118206B9 (en) | 2007-02-09 | 2018-08-29 | Visen Medical, Inc. | Polycyclo dyes and use thereof |
EP2532643A1 (en) | 2007-06-08 | 2012-12-12 | MannKind Corporation | IRE-1A Inhibitors |
WO2009014674A1 (en) * | 2007-07-23 | 2009-01-29 | Sirtris Pharmaceuticals, Inc. | Heterocyclylamides as gut microsomal triglyceride transport protein inhibitors |
JP5571000B2 (ja) * | 2008-01-16 | 2014-08-13 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | メトフォルミンおよびmtp阻害剤の組み合わせ物 |
US20090197947A1 (en) * | 2008-02-01 | 2009-08-06 | The Research Foundation Of State University Of New York | Medicaments and methods for lowering plasma lipid levels and screening drugs |
EP2522657B1 (en) * | 2010-01-06 | 2016-08-03 | Takeda Pharmaceutical Company Limited | Indole derivative |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
SG184987A1 (en) | 2010-04-22 | 2012-11-29 | Vertex Pharma | Process of producing cycloalkylcarboxamido-indole compounds |
US9409880B2 (en) * | 2011-01-20 | 2016-08-09 | The Regents Of The University Of Colorado, A Body Corporate | Modulators of TLR3/dsRNA complex and uses thereof |
CN102108070B (zh) * | 2011-01-26 | 2013-05-22 | 上海优贝德生物医药有限公司 | 5-氨基苯并呋喃-2-甲酸酯及其中间体的制备方法 |
CA2878057A1 (en) | 2012-07-16 | 2014-01-23 | Rossitza Gueorguieva Alargova | Pharmaceutical compositions of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof |
CA2903657A1 (en) | 2013-02-27 | 2014-09-04 | Shionogi & Co., Ltd. | Indole and azaindole derivatives each having ampk-activating activity |
WO2015121877A2 (en) * | 2014-02-17 | 2015-08-20 | Hetero Research Foundation | Polymorphs of lomitapide and its salts |
CN103880797B (zh) * | 2014-03-26 | 2015-12-02 | 沈阳大学 | 苯并呋喃类化合物及其医药用途 |
EP4223294A1 (en) | 2014-04-15 | 2023-08-09 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
CA2963792A1 (en) | 2014-10-06 | 2016-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US10738030B2 (en) | 2016-03-31 | 2020-08-11 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
ES2900263T3 (es) | 2016-09-30 | 2022-03-16 | Vertex Pharma | Modulador de regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso de fabricación del modulador |
EP3551622B1 (en) | 2016-12-09 | 2020-10-07 | Vertex Pharmaceuticals Incorporated | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
CA3066084A1 (en) | 2017-06-08 | 2018-12-13 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
AU2018304168B2 (en) | 2017-07-17 | 2023-05-04 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
US11434201B2 (en) | 2017-08-02 | 2022-09-06 | Vertex Pharmaceuticals Incorporated | Processes for preparing pyrrolidine compounds |
EP3697774A1 (en) | 2017-10-19 | 2020-08-26 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of cftr modulators |
EP3720849A2 (en) | 2017-12-08 | 2020-10-14 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
WO2019200246A1 (en) | 2018-04-13 | 2019-10-17 | Alexander Russell Abela | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4022900A (en) | 1970-09-09 | 1977-05-10 | Marion Laboratories, Inc. | Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents |
US4397855A (en) | 1981-06-26 | 1983-08-09 | Warner-Lambert Company | 4-(Substituted)-α, α-dimethyl-1-piperazine pentanoic acids and derivatives as anti-arteriosclerotic agents and method |
US4647576A (en) * | 1984-09-24 | 1987-03-03 | Warner-Lambert Company | Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis |
US5416009A (en) | 1991-01-23 | 1995-05-16 | The United States Of America | Nucleotide molecule encoding a specific Onchocerca volvulus antigen for the immunodiagnosis of onchocerciasis |
US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
ZA931601B (en) | 1992-03-06 | 1993-10-05 | Squibb & Sons Inc | Microsomal triglyceride transfer protein |
GB9225141D0 (en) | 1992-12-01 | 1993-01-20 | Smithkline Beecham Corp | Chemical compounds |
US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
FR2723739B1 (fr) * | 1994-08-19 | 1997-02-14 | Sanofi Sa | Derives de glycinamide, procedes pour leur preparation et medicaments les contenant. |
PT832069E (pt) | 1995-06-07 | 2003-06-30 | Pfizer | Derivados de tetrahidro-isoquinolin-6-il amida do acido bifenilo-2-carboxilico sua preparacao e sua utilizacao como inibidores de proteina de transferencia de triglicerido microsomal e/ou da secrecao de apolipoproteina b (apo b) |
ATE233734T1 (de) | 1995-06-07 | 2003-03-15 | Pfizer | Biphenyl-2-carbonsäure-tetrahydro-isochinolin-6 yl amid derivate, deren hestellung und deren verwendung als inhibitoren des mikrosomalen triglycerid-transfer-proteins und/oder der apolipoprotein b (apo b) sekretion |
WO1996040640A1 (en) * | 1995-06-07 | 1996-12-19 | Pfizer Inc. | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION |
CA2244729C (en) | 1996-02-02 | 2005-08-23 | Merritt, Brigitte | Device for processing a strand of plastic material |
US5827875A (en) | 1996-05-10 | 1998-10-27 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
CN1238764A (zh) | 1996-11-27 | 1999-12-15 | 美国辉瑞有限公司 | 可抑制ApoB-分泌物/MTP的酰胺 |
WO1998027979A1 (en) | 1996-12-20 | 1998-07-02 | Bristol-Myers Squibb Company | Heterocyclic inhibitors of microsomal triglyceride transfer protein and method |
US6066653A (en) | 1997-01-17 | 2000-05-23 | Bristol-Myers Squibb Co. | Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs |
US5968950A (en) | 1997-06-23 | 1999-10-19 | Pfizer Inc | Apo B-secretion/MTP inhibitor hydrochloride salt |
TW460478B (en) * | 1997-08-15 | 2001-10-21 | Chugai Pharmaceutical Co Ltd | Phenethylamine derivatives |
JP2959765B2 (ja) | 1997-12-12 | 1999-10-06 | 日本たばこ産業株式会社 | 3−ピペリジル−4−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物 |
ATE293599T1 (de) | 1997-12-24 | 2005-05-15 | Aventis Pharma Gmbh | Indolderivate als faktor xa inhibitoren |
EP1080724A4 (en) | 1998-05-22 | 2004-06-23 | Nippon Shinyaku Co Ltd | COMPOSITIONS FOR REDUCING MTP ACTIVITY |
WO1999063929A2 (en) | 1998-06-08 | 1999-12-16 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
CO5090829A1 (es) * | 1998-07-21 | 2001-10-30 | Novartis Ag | Compuestos organicos de la formula i, utiles como inhibido res de la proteina de transferencia de triglicerido microso mal y de la secrecion de la apolipoproteina b. |
US6197798B1 (en) | 1998-07-21 | 2001-03-06 | Novartis Ag | Amino-benzocycloalkane derivatives |
CA2375920A1 (en) * | 1999-06-14 | 2000-12-21 | Eli Lilly And Company | Compounds |
DE19933926A1 (de) | 1999-07-20 | 2001-01-25 | Boehringer Ingelheim Pharma | Biphenylderivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
DE19945594A1 (de) * | 1999-09-23 | 2001-03-29 | Boehringer Ingelheim Pharma | Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
CA2325358C (en) * | 1999-11-10 | 2005-08-02 | Pfizer Products Inc. | 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b |
DE19963234A1 (de) | 1999-12-27 | 2002-01-24 | Boehringer Ingelheim Pharma | Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
DE19963235A1 (de) | 1999-12-27 | 2001-07-05 | Boehringer Ingelheim Pharma | Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
WO2001053260A1 (en) | 2000-01-18 | 2001-07-26 | Novartis Ag | Carboxamides useful as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion |
WO2001077077A1 (en) | 2000-04-10 | 2001-10-18 | Novartis Ag | Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion |
GB0013383D0 (en) | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
GB0013346D0 (en) | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
GB0013378D0 (en) | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Use of therapeutic benzamide derivatives |
DE10033337A1 (de) | 2000-07-08 | 2002-01-17 | Boehringer Ingelheim Pharma | Biphenylcarbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
US20020032238A1 (en) | 2000-07-08 | 2002-03-14 | Henning Priepke | Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments |
FR2816940A1 (fr) | 2000-11-23 | 2002-05-24 | Lipha | Derives de 4-(biphenylcarbonylamino)-piperidine, compositions les contenant et leur utilisation |
GB0109287D0 (en) | 2001-04-12 | 2001-05-30 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
JP4139325B2 (ja) * | 2001-06-28 | 2008-08-27 | ファイザー・プロダクツ・インク | ミクロソーム・トリグリセリド・トランスファータンパク質(mtp)及び/又はアポリポタンパク質b(apob)分泌の阻害剤としてのトリアミド置換インドール、ベンゾフラン及びベンゾチオフェン |
KR100717098B1 (ko) | 2002-02-28 | 2007-05-10 | 니뽄 다바코 산교 가부시키가이샤 | 에스테르 화합물 및 그 의약 용도 |
-
2002
- 2002-05-24 JP JP2003508914A patent/JP4139325B2/ja not_active Expired - Lifetime
- 2002-05-24 NZ NZ528752A patent/NZ528752A/en not_active IP Right Cessation
- 2002-05-24 AT AT02780923T patent/ATE405548T1/de active
- 2002-05-24 IL IL15851602A patent/IL158516A0/xx not_active IP Right Cessation
- 2002-05-24 HU HU0400348A patent/HU229551B1/hu not_active IP Right Cessation
- 2002-05-24 AU AU2002307839A patent/AU2002307839B2/en not_active Ceased
- 2002-05-24 EE EEP200400040A patent/EE05452B1/xx not_active IP Right Cessation
- 2002-05-24 EP EP02780923A patent/EP1404653B1/en not_active Expired - Lifetime
- 2002-05-24 BR BR0210616-7A patent/BR0210616A/pt active Search and Examination
- 2002-05-24 PL PL02367680A patent/PL367680A1/xx unknown
- 2002-05-24 DE DE60228447T patent/DE60228447D1/de not_active Expired - Lifetime
- 2002-05-24 SI SI200230732T patent/SI1404653T1/sl unknown
- 2002-05-24 KR KR1020057025027A patent/KR100575944B1/ko not_active IP Right Cessation
- 2002-05-24 GE GEAP20027236A patent/GEP20063720B/en unknown
- 2002-05-24 RS YUP-1004/03A patent/RS50712B/sr unknown
- 2002-05-24 SK SK1610-2003A patent/SK287806B6/sk not_active IP Right Cessation
- 2002-05-24 DK DK02780923T patent/DK1404653T3/da active
- 2002-05-24 ES ES02780923T patent/ES2307799T3/es not_active Expired - Lifetime
- 2002-05-24 PT PT02780923T patent/PT1404653E/pt unknown
- 2002-05-24 CZ CZ20033558A patent/CZ20033558A3/cs unknown
- 2002-05-24 UA UA20031212657A patent/UA75660C2/uk unknown
- 2002-05-24 CA CA002451474A patent/CA2451474C/en not_active Expired - Fee Related
- 2002-05-24 GE GE5350A patent/GEP20053720B/en unknown
- 2002-05-24 WO PCT/IB2002/001876 patent/WO2003002533A1/en active IP Right Grant
- 2002-05-24 OA OA1200300327A patent/OA12626A/en unknown
- 2002-05-24 CN CN028130219A patent/CN1522246B/zh not_active Expired - Fee Related
- 2002-05-24 CN CN2006100941142A patent/CN1880304B/zh not_active Expired - Fee Related
- 2002-05-24 EA EA200301310A patent/EA007008B1/ru not_active IP Right Cessation
- 2002-05-24 MX MXPA03011707A patent/MXPA03011707A/es active IP Right Grant
- 2002-05-24 KR KR1020037017167A patent/KR100575919B1/ko not_active IP Right Cessation
- 2002-05-24 TN TNPCT/IB2002/001876A patent/TNSN03146A1/fr unknown
- 2002-06-20 US US10/177,858 patent/US6720351B2/en not_active Expired - Fee Related
- 2002-06-21 TW TW094146513A patent/TW200628447A/zh unknown
- 2002-06-21 TW TW091113664A patent/TWI313264B/zh not_active IP Right Cessation
- 2002-06-26 MY MYPI20022415A patent/MY129328A/en unknown
- 2002-06-26 AR ARP020102408A patent/AR036158A1/es active IP Right Grant
- 2002-06-27 GT GT200200136A patent/GT200200136A/es unknown
- 2002-06-27 PE PE2002000580A patent/PE20030135A1/es not_active Application Discontinuation
- 2002-06-27 AP APAP/P/2002/002567A patent/AP1649A/en active
- 2002-06-27 UY UY27360A patent/UY27360A1/es unknown
- 2002-06-28 PA PA20028549301A patent/PA8549301A1/es unknown
-
2003
- 2003-08-13 US US10/639,855 patent/US6949572B2/en not_active Expired - Fee Related
- 2003-08-13 US US10/639,854 patent/US6979692B2/en not_active Expired - Fee Related
- 2003-10-07 ZA ZA200307818A patent/ZA200307818B/en unknown
- 2003-10-09 IS IS6988A patent/IS2603B/is unknown
- 2003-11-17 CR CR7151A patent/CR7151A/es not_active Application Discontinuation
- 2003-12-16 NO NO20035607A patent/NO326700B1/no not_active IP Right Cessation
- 2003-12-17 HR HR20031051A patent/HRP20031051B1/xx not_active IP Right Cessation
- 2003-12-22 MA MA27457A patent/MA27045A1/fr unknown
- 2003-12-22 BG BG108487A patent/BG108487A/bg unknown
- 2003-12-23 EC EC2003004925A patent/ECSP034925A/es unknown
-
2004
- 2004-09-14 HK HK07101214.1A patent/HK1096665A1/xx not_active IP Right Cessation
- 2004-09-14 HK HK04106993.0A patent/HK1064369A1/xx not_active IP Right Cessation
-
2005
- 2005-08-02 US US11/196,563 patent/US7482368B2/en not_active Expired - Fee Related
-
2006
- 2006-02-10 US US11/351,571 patent/US7348355B2/en not_active Expired - Fee Related
-
2008
- 2008-10-13 CY CY20081101126T patent/CY1108407T1/el unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022111222A1 (zh) * | 2020-11-26 | 2022-06-02 | 安润医药科技(苏州)有限公司 | 作为前列腺素ep4受体拮抗剂的酰胺衍生物及其用途 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1522246A (zh) | 作为微粒体甘油三酯转移蛋白(mtp)和/或载脂蛋白b(apo b)分泌抑制剂的三酰胺取代的吲哚、苯并呋喃及苯并噻吩 | |
CN1242995C (zh) | 化合物,它们的用途和制备方法 | |
CN1078889C (zh) | 非肽类速激肽受体拮抗剂 | |
CN1297546C (zh) | 带有取代氨甲基的N-(芳基磺酰基)-β-氨基酸衍生物、其制备方法和含有该化合物的药物组合物 | |
CN1259307C (zh) | 酰化的二氢化茚基胺及其作为药物的用途 | |
CN1131210C (zh) | 杂环类酰胺化合物及其医药用途 | |
CN1243723C (zh) | 作为fsad的nep抑制剂的n-苯丙基环戊基取代的戊二酰胺衍生物 | |
CN1016778B (zh) | 螺-取代的戊二酸单酰胺 | |
CN1244575C (zh) | 磺酰基烷酰氨基羟乙氨基磺酰胺逆转录病毒蛋白酶抑制剂 | |
CN101076516A (zh) | 作为丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的硫化合物 | |
CN1213036C (zh) | 新的酰胺类衍生物 | |
CN1238760A (zh) | N-(芳基/杂芳基/烷基乙酰基)氨基酸酰胺类,含有这类化合物的药物组合物,及用这类化合物抑制β-淀粉样肽释放和或合成的方法 | |
CN1173867A (zh) | 吲哚基神经肽y受体拮抗剂 | |
CN1149223C (zh) | 杂环羰基氨基酸羟乙氨基磺酰胺逆转录病毒蛋白酶抑制剂 | |
CN1659156A (zh) | 新的胍基苯甲酰胺 | |
CN1320037A (zh) | 抗病毒的吲哚氧代乙酰基哌嗪衍生物 | |
CN1432022A (zh) | 含有烷基和芳基丙氨酸p2部分的丙型肝炎病毒的大环ns3-丝氨酸蛋白酶抑制剂 | |
CN1642599A (zh) | Acc抑制剂 | |
CN1214339A (zh) | 吡唑衍生物、其制备方法和在药物中的应用 | |
CN1276790A (zh) | 酰胺基噻唑衍生物及其制备方法与药物组合物 | |
CN1040986A (zh) | 环烷基取代的戊二酰胺衍生物的制备 | |
CN1119856A (zh) | Hiv逆转录酶抑制剂 | |
CN1527827A (zh) | 治疗性杂环化合物 | |
CN1304406A (zh) | 作为玻连蛋白拮抗剂的杂环甘氨酰β-丙氨酸衍生物 | |
CN1294577A (zh) | 钾通道抑制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1064369 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1064369 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: PAH AMERICA 15 CO., LTD. Free format text: FORMER OWNER: PFIZER PRODUCTS INC. Effective date: 20130508 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee |
Owner name: ZOETIS P LLC Free format text: FORMER NAME: PAH AMERICA 15 CO., LTD. |
|
CP03 | Change of name, title or address |
Address after: New jersey, USA Patentee after: Zotis P LLC Address before: American New York Patentee before: PAH USA 15 LLC |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130508 Address after: American New York Patentee after: PAH USA 15 LLC Address before: American Connecticut Patentee before: Pfizer Products Inc. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100421 Termination date: 20150524 |
|
EXPY | Termination of patent right or utility model |